HK1004472A1 - Process for the preparation of a medicament for oral or topical administration in the treatment of leishmaniasis - Google Patents

Process for the preparation of a medicament for oral or topical administration in the treatment of leishmaniasis

Info

Publication number
HK1004472A1
HK1004472A1 HK98103738A HK98103738A HK1004472A1 HK 1004472 A1 HK1004472 A1 HK 1004472A1 HK 98103738 A HK98103738 A HK 98103738A HK 98103738 A HK98103738 A HK 98103738A HK 1004472 A1 HK1004472 A1 HK 1004472A1
Authority
HK
Hong Kong
Prior art keywords
group
medicament
oral
treatment
topical administration
Prior art date
Application number
HK98103738A
Other languages
English (en)
Inventor
Hansjorg Eibl
Clemens Unger
Jurgen Engel
Original Assignee
Max Planck Gesellschaft
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Asta Medica Ag filed Critical Max Planck Gesellschaft
Publication of HK1004472A1 publication Critical patent/HK1004472A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HK98103738A 1991-09-27 1998-05-01 Process for the preparation of a medicament for oral or topical administration in the treatment of leishmaniasis HK1004472A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4132344A DE4132344A1 (de) 1991-09-27 1991-09-27 Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Publications (1)

Publication Number Publication Date
HK1004472A1 true HK1004472A1 (en) 1998-11-27

Family

ID=6441697

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98103738A HK1004472A1 (en) 1991-09-27 1998-05-01 Process for the preparation of a medicament for oral or topical administration in the treatment of leishmaniasis

Country Status (13)

Country Link
US (1) US5980915A (xx)
EP (1) EP0534445B1 (xx)
JP (2) JP3587862B2 (xx)
KR (2) KR100270255B1 (xx)
AT (1) ATE177950T1 (xx)
BR (1) BR9203768A (xx)
DE (2) DE4132344A1 (xx)
DK (1) DK0534445T3 (xx)
ES (1) ES2132101T3 (xx)
GR (1) GR3030016T3 (xx)
HK (1) HK1004472A1 (xx)
MX (1) MX9205466A (xx)
SG (1) SG49692A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254879B1 (en) * 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
US5681829A (en) * 1992-10-08 1997-10-28 Shaman Pharmaceuticals, Inc. Class of phosphocholine derivatives having antifungal activity
DE4305553A1 (de) * 1992-12-18 1994-06-23 Rhone Poulenc Rorer Gmbh Pharmazeutisches und/oder kosmetisches Mittel
NZ505648A (en) 1998-01-22 2002-10-25 Zentaris Ag Hexadecylphosphocholine (HPC) and a flow controlling agent and/or a lubricant and a filler in a daily dosage of 10-250 mg
DE19835611A1 (de) * 1998-08-06 2000-02-10 Max Planck Gesellschaft Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
DE10025124B4 (de) * 2000-05-20 2015-07-16 Beiersdorf Ag Kombinationen von Glycerinmonoalkylethern und Aryl-substituierten Alkoholen
DE10025122A1 (de) * 2000-05-20 2001-11-22 Beiersdorf Ag Kombinationen von Clycerinmonoalkylethern und Fettsäreglyceriden
BG64968B1 (bg) * 2000-08-07 2006-11-30 Asta Medica Aktiengesellschaft Твърди фармацевтични състави, съдържащи милтефозин за орално приложение при лечението на leishmaniasis
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
WO2004041167A2 (en) * 2002-10-30 2004-05-21 Theodora Calogeropoulou Antiprotozoal ring-substituted phospholipids
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
EP1962862B1 (en) * 2005-12-19 2013-09-04 Æterna Zentaris GmbH Alkyl phospholipid derivatives with reduced cytotoxicity and uses therof
UA99434C2 (ru) * 2005-12-19 2012-08-27 Аетерна Центаріс Гмбх Применение производных алкилфосфолипидов со сниженной цитотоксичностью
DE102007014375A1 (de) * 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oleylphosphocholin
BR112012000476A2 (pt) 2009-07-09 2016-11-22 Expergen Drug Dev Gmbh forma farmacêutica líquida de alquilfosfocolina e método de preparação da mesma.
BR112013012652A2 (pt) * 2010-11-22 2016-09-06 Dafra Pharma Res & Dev Bvba forma de dosagem sólida de oleil fosfocolina para administração oral, forma de dosagem sólida, e método para a preparação de uma forma de dosagem sólida
BR112020020759A2 (pt) * 2018-04-10 2021-01-19 Cellectar Biosciences, Inc. Conjugados de fosfolipídeos-flavaglinas e métodos de utilização para a terapia direcionada a câncer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
CA1338627C (en) * 1985-12-04 1996-10-01 Hansjorg Eibl Pharmaceuticals based on phosphoric acid esters for use in tumor therapy, and process for their preparation
US5087721A (en) * 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
WO1989010370A1 (en) * 1988-04-19 1989-11-02 Cl-Pharma Aktiengesellschaft New alkylphosphono- and phosphoserines, method for preparing them, and pharmaceutical substances containing them

Also Published As

Publication number Publication date
KR100270255B1 (ko) 2002-09-04
DK0534445T3 (da) 1999-10-18
JP3587862B2 (ja) 2004-11-10
JP2004315540A (ja) 2004-11-11
EP0534445A1 (de) 1993-03-31
ATE177950T1 (de) 1999-04-15
SG49692A1 (en) 1998-06-15
US5980915A (en) 1999-11-09
KR930005622A (ko) 1993-04-20
KR100283783B1 (ko) 2001-02-15
DE59209663D1 (de) 1999-04-29
JPH06263643A (ja) 1994-09-20
GR3030016T3 (en) 1999-07-30
EP0534445B1 (de) 1999-03-24
BR9203768A (pt) 1993-04-20
ES2132101T3 (es) 1999-08-16
DE4132344A1 (de) 1993-04-01
MX9205466A (es) 1993-05-01

Similar Documents

Publication Publication Date Title
GR3030016T3 (en) Process for the preparation of a medicament for oral or topical administration in the treatment of leishmaniasis
CZ158695A3 (en) Pyrazolopyrimidine compounds as such and for treating diseases and pharmaceutical preparations based thereon
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
CA2039197A1 (en) Pharmaceutic Formulation for the Treatment of Alcoholism
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
CA2044746A1 (en) Polypeptide compound and a process for preparation thereof
HU9301579D0 (en) Compounds having medical effect
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
HK1006708A1 (en) Derivatives of substituted cyclohexane their process of preparation and their application with the treatment of diseases
RU94045278A (ru) Применение 2-фенил-3-ароилбензтиофенов для ингибирования вазомоторных симптомов и сопутствующих психологических нарушений, ассоциированных с постклимактерическим синдромом
CA2003289A1 (en) Use of trifluoromethylphenyl-tetrahydropyridines for the preparation of pharmaceutical compositions useful for the treatment of anxiety and anxio-depressive disorders
HU9200335D0 (en) Medical products with human interleukin-2 content
CA2331297A1 (en) Hygromycin a derivatives
IT1256178B (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
DK492989D0 (da) Aminopyrrolidinon, farmaceutisk praeparat indeholdende en saadan forbindelse og fremgangsmaade til fremstilling deraf
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
HUT48265A (en) Process for producing phosphorous-containing 2-isoxazolines and isoxazoles and pharmaceutical compositions containing them or theyr salts as active components
EP0551844A3 (xx)
DE69818060D1 (de) Polyhydroxyalkylpyrazine derivate, deren herstellung,diese enthaltende arzneimitteln
JPS554397A (en) Novel n11benzoylln22phenyll1*33diaminopropane 22ol*its manufacture and medicine containing it for therapy of acute and chronic gastritis
AU5768298A (en) Use of benzoylalkyl-1,2,3,6-tetrahydropyridins
IE781718L (en) Imidazole derivatives
IT1248558B (it) Derivati della fisovenina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
DE3786168D1 (de) Verwendung von para-aminobenzoesaeure zur herstellung eines arzneimittels zur bekaempfung von photoallergien.

Legal Events

Date Code Title Description
PF Patent in force
AS Change of ownership

Owner name: ZENTARIS GMBH

Free format text: FORMER OWNER(S): ZENTARIS AG, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER

Owner name: WISSENSCHAFTEN E. V. TO MAX-PLANCK-GESELLSCHAFT ZU

Free format text: FORMER OWNER(S): ZENTARIS AG, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090924